NASDAQ:XCUR Exicure Q4 2025 Earnings Report $1.46 +0.21 (+16.40%) As of 10:37 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Exicure EPS ResultsActual EPS-$0.46Consensus EPS -$18.60Beat/MissBeat by +$18.14One Year Ago EPSN/AExicure Revenue ResultsActual RevenueN/AExpected Revenue$1.64 millionBeat/MissN/AYoY Revenue GrowthN/AExicure Announcement DetailsQuarterQ4 2025Date3/25/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsExicure's next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules. Conference Call ResourcesSEC FilingEarnings HistoryCompany Profile Exicure Earnings HeadlinesExicure Announces Planned Issuance of Common Stock to Settle $1.0 Million Milestone Payment to GPCR TherapeuticsAugust 3, 2026 | quiverquant.comQExicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity IssuanceAugust 3, 2026 | globenewswire.comWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax that year in exchange for potential tax-free qualified growth later. Key questions remain: how much to convert, where the tax payment comes from, and whether this years income leaves room. Roth IRAs also avoid lifetime required minimum distributions. A fiduciary financial advisor can help size a conversion around your specific tax situation and goals.September 8 at 1:00 AM | SmartAsset (Ad)Exicure Reaches Preliminary Settlement in Derivative LawsuitsJuly 9, 2026 | theglobeandmail.comExicure Announces Board and Committee ChangesJune 30, 2026 | globenewswire.comExicure, Inc.: Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementJune 11, 2026 | finanznachrichten.deSee More Exicure Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Exicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exicure and other key companies, straight to your email. Email Address About ExicureExicure (NASDAQ:XCUR) is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system. The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology. By leveraging the unique structural properties of SNA constructs, Exicure aims to improve cellular uptake, enhance pharmacokinetics and reduce off‐target effects compared with traditional nucleic acid therapies. Founded on technology originating from Northwestern University, Exicure is headquartered in Skokie, Illinois, where it conducts its research, preclinical studies and early‐stage development activities. The company completed its initial public offering on the Nasdaq exchange under the ticker XCUR and maintains a focused R&D footprint in the Chicago area. Exicure collaborates with academic institutions and biopharmaceutical partners to advance its SNA platform and expand its therapeutic reach. Guided by a management team with deep expertise in biotechnology innovation, the company is working to translate its nanotechnology into novel treatments for patients with high‐unmet medical needs around the world.View Exicure ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/31 - 09/04Why Guidewire’s Post-Earnings Plunge May Not LastPalo Alto vs. Zscaler: Which Cybersecurity Stock Looks Stronger After Earnings?Short Sellers Are Betting Against 3 AI Infrastructure Stocks—What Could Turn the Tide?Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key SignalLululemon’s Earnings Beat Hid a Bigger Problem for Its Turnaround Story3 Stocks With September Catalysts Investors Shouldn’t Ignore Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
